Growth factor receptors like EGFR, HER-2, and c-Kit have recently emerged as promising targets for novel therapeutic agents in malignancies such as lung cancer (Shepherd et al, 2005), breast cancer (Slamon et al, 2001), and gastrointestinal stromal tumour (GIST) (Heinrich et al, 2002). Here, KIT is linked to breast carcinoma.